AbbVie Reports Full-Year and Fourth-Quarter 2021 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/3/2026
- Wall Street rallies as Fed's Waller eases rate hike fears
- Fed’s Waller open to September rate hold - if disinflation holds up
- Broadcom raises AI chip forecast as Big Tech keeps writing bigger checks
- Nvidia to acquire AI platform Hugging Face in landmark $12.9B deal
- Tesla to unveil Cybercab Texas today, details are few
Abbvie (ABBV) PT Raised to $154 at BMO Capital
February 3, 2022 7:19 AM ESTBMO Capital analyst Gary Nachman raised the price target on Abbvie (NYSE: ABBV) to $154.00 (from $153.00) while maintaining an Outperform rating.
The analyst commented, "4Q good overall despite slight revenue shortfall as many key growth drivers performed well and better op. leverage drove EPS... More
AbbVie (ABBV) Tops Q4 EPS by 3c, Offers Guidance
February 2, 2022 7:44 AM ESTAbbVie (NYSE: ABBV) reported Q4 EPS of $3.31, $0.03 better than the analyst estimate of $3.28. Revenue for the quarter came in at $14.89 billion versus the consensus estimate of $14.95 billion.
GUIDANCE:
AbbVie sees FY2022 EPS of $14.00-$14.20, versus the consensus of... More
